Allogene Therapeutics Inc (ALLO) 13F Holders & Ownership Data (210 Funds, Q2 2026)

ALLO ranks #2889 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ALLO is a top-conviction position for Pfizer Inc — at 27.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ALLO belongs to BlackRock, Inc., but the position matters far more to Pfizer Inc, who has 27.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Frazier Life Sciences Management, L.P. has added to its ALLO position for two straight quarters, increasing it by $41.4M to reach $46.7M today.

Jane Street Group, LLC has trimmed its ALLO position for two straight quarters, cutting it by $2.8M while still holding $146.0K.

ALLO is down 0.5% today, but institutions show net buying of $282.7M this quarter — a divergence between today's price move and the underlying institutional flow.

ALLO reported a net loss of $165.5M over the trailing twelve months.

• Not yet profitable — net loss of $165.5M over the trailing twelve months
• Net income improved year over year, from -$236.9M to -$165.5M
• Operating cash flow was negative, using $149.2M in cash
• Current ratio of 7.93x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.42x equity — within a conventional range